Drug Trial Radar · NCT05342792
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
Last checked: Nov 20, 2026Latest source record: Apr 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
556
Planned (sponsor's estimate)
Start
Apr 17, 2022
Primary completion
Jun 2027
Study completion Jun 2029
Sponsor
- Lead sponsor
- Sun Yat-sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Tongji Hospital; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Xiangya Hospital of Central South University; Affiliated Cancer Hospital of Guizhou Medical University; Cancer Hospital of Guangxi Medical University; First People's Hospital of Foshan; Chongqing University Cancer Hospital; Hubei Cancer Hospital; Hunan Cancer Hospital; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; Fifth Affiliated Hospital, Sun Yat-Sen University; Shandong Provincial Hospital
- First posted
- Apr 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is aimed to investigate whether additional adjuvant PD-1 antibody treatment could improve survival in high-risk nasopharyngeal carcinoma compared to metronomic capecitabine alone.
Conditions
- Nasopharyngeal Carcinoma
Interventions
PD-1 antibodyDrug
Tislelizumab:200 mg per dose, intravenous infusion over 30 minutes, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
CapecitabineDrug
Capecitabine : 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- failure-free survivalTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.